甲福明通过加强巨细胞的抗微生物功能来改善Mycobacterium avium感染
Sindre Dahl Mediaas1,2, Markus Haug1,2, Claire Louet1
1Centre of Molecular Inflammation Research, Department of Molecular and Clinical Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Frontiers in immunology
|December 31, 2024
概括
糖尿病药物甲福明显著降低了小鼠感染Mycobacterium avium的肺部细菌负载. 甲胺增强了巨细胞的抗微生物防御,这表明它有可能作为非结核性真菌菌菌感染的辅助疗法.
科学领域:
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非结核菌 (NTM) 感染,特别是Mycobacterium avium (Mav),在全球范围内正在增加.
- 目前对Mav感染的治疗方案是长期的,表现出抗生素耐药性,并且治愈率低,需要新的治疗策略.
- 将标准化疗与宿主导免疫系统调节剂结合起来,是改善治疗结果的有希望的方法.
研究的目的:
- 为了研究二型糖尿病药物甲福明的疗效,作为Mycobacterium avium (Mav) 感染的辅助治疗.
- 确定甲胺是否可以改善对小鼠模型中的Mav感染的控制,并阐明其潜在的作用机制.
主要方法:
- C57BL/6小鼠被内鼻感染了Mav,并接受了3周的甲福明治疗.
- 评估了器官的细菌负载,肺部病理,炎症性细胞因子和免疫细胞概况.
- 机理学研究涉及用单独或与抑制剂一起用甲福明治疗感染Mav的巨细胞,以评估细菌负担和细胞成熟.
主要成果:
- 甲胺治疗显著降低了感染小鼠的肺部菌株负担.
- 在整体肺病理或免疫细胞组成中没有观察到重大变化,尽管发现IFNγ和Mav特异性T细胞增加的趋势.
- 甲福明通过调节新陈代谢,激活AMPK,增加线粒体ROS和细胞成熟,并增强I型免疫力来增强巨细胞的抗菌能力.
结论:
- 甲胺有效地改善了小鼠中Mycobacterium avium感染的控制.
- 主要机制涉及加强巨细胞的抗微生物防御.
- 甲胺显示出作为非结核性真菌菌菌感染的辅助疗法的潜力.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Diabetes: Management and Pharmacotherapy
203
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
203
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
104
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
104
Oral Hypoglycemic Agents: Glinides
108
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
108
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K


